These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Effects of rituximab on a patient with Waldenström's macroglobulinaemia with deletion 13q14. Mori A; Tamaru J; Kondo H Eur J Haematol; 2002; 69(5-6):321-3. PubMed ID: 12460239 [TBL] [Abstract][Full Text] [Related]
25. Waldenstrom's macroglobulinemia: is there a place and time for a cease-fire? Zinzani PL; Tani M; Alinari L; Stefoni V; Baccarani M Leuk Res; 2003 May; 27(5):465-6. PubMed ID: 12620298 [No Abstract] [Full Text] [Related]
30. [Waldenström's macroglobulinemia--the experts opinion about new therapeutic possibilities and response criteria]. Jurczyszyn A; Skotnicki AB Pol Arch Med Wewn; 2004 Sep; 112(3):1113-21. PubMed ID: 15727094 [No Abstract] [Full Text] [Related]
31. Resolution of Waldenström's macroglubulinemia related isolated neutropenia by immunochemotherapy. van Gelder M; van Marion A; Goossens V; Bommer M; Leblond V Am J Hematol; 2011 Apr; 86(4):380-2. PubMed ID: 21442645 [No Abstract] [Full Text] [Related]
32. Acute renal failure secondary to severe type I cryoglobulinemia following rituximab therapy for Waldenström's macroglobulinemia. Shaikh A; Habermann TM; Fidler ME; Kumar S; Leung N Clin Exp Nephrol; 2008 Aug; 12(4):292-295. PubMed ID: 18288560 [TBL] [Abstract][Full Text] [Related]
33. Hepatocellular carcinoma followed by Waldenström's macroglobulinemia: a case report. Hasegawa K; Kubota K; Hirai H; Imai Y; Midorikawa Y; Makuuchi M Hepatogastroenterology; 2000; 47(33):842-5. PubMed ID: 10919044 [TBL] [Abstract][Full Text] [Related]
34. [Effective treatment with rituximab in two patients with Waldenström macroglobulinemia]. Yoshimi A; Arai S; Iijima K; Iki S; Usuki K; Urabe A Rinsho Ketsueki; 2005 Oct; 46(10):1109-13. PubMed ID: 16440772 [TBL] [Abstract][Full Text] [Related]
35. Appropriateness of applying the response criteria for multiple myeloma to Waldenstrom's macroglobulinemia? Bladé J; Montoto S; Rosiñol L; Montserrat E Semin Oncol; 2003 Apr; 30(2):329-31. PubMed ID: 12720163 [TBL] [Abstract][Full Text] [Related]
36. Rituximab-based treatments in Waldenström's macroglobulinemia. Dimopoulos MA; Kastritis E; Roussou M; Eleutherakis-Papaiakovou E; Migkou M; Gavriatopoulou M; Tassidou A; Terpos E Clin Lymphoma Myeloma; 2009 Mar; 9(1):59-61. PubMed ID: 19362975 [TBL] [Abstract][Full Text] [Related]
37. The optimized anti-CD20 monoclonal antibody ublituximab bypasses natural killer phenotypic features in Waldenström macroglobulinemia. Le Garff-Tavernier M; Herbi L; de Romeuf C; Azar N; Roos-Weil D; Bonnemye P; Urbain R; Leblond V; Merle-Beral H; Vieillard V Haematologica; 2015 Apr; 100(4):e147-51. PubMed ID: 25552707 [No Abstract] [Full Text] [Related]
38. Nodular amyloidosis of all four eyelids: first presenting symptom of Waldenström macroglobulinaemia. Jacoby S; Toft PB; Prause JU; Philip P; Heegaard S Acta Ophthalmol; 2014 Jun; 92(4):392-3. PubMed ID: 23601930 [No Abstract] [Full Text] [Related]
39. The International Prognostic Scoring System for Waldenstrom's macroglobulinemia is applicable in patients treated with rituximab-based regimens. Dimopoulos MA; Kastritis E; Delimpassi S; Zomas A; Kyrtsonis MC; Zervas K Haematologica; 2008 Sep; 93(9):1420-2. PubMed ID: 18641029 [No Abstract] [Full Text] [Related]